Dataset opportunity
Eumediq — 医疗影像数据集机会
Eumediq 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2024 年为 17.5 亿美元，复合年增长率为 30%（来源：rootsanalysis.com）[7]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Eumediq 持有一个专有的医疗影像数据集，该数据集源自其医疗设备相关的临床活动。此集合丰富了相应的医疗记录和监管文件，提供了一个全面且真实的数据源，非常适合训练、测试和验证诊断人工智能模型。数据集的结构经过优化，可用于开发需要高质量、情境化证据的算法。
该数据定位于快速增长的医疗影像人工智能市场，该市场在 2024 年的估值为17.5 亿美元，预计将以30% 的复合年增长率扩张。[7] 虽然访问受到严格的 GDPR 和 MDR 合规性限制，并且需要强大的匿名化协议，但此临床数据的稀有性和深度提供了显著的竞争优势。它代表了寻求在具有巨大增长潜力的市场中创建高度准确且合规的诊断解决方案的 AI 开发者的关键资产。⚠ 尽职调查（有价值的数据，可协商访问）：高度敏感的医疗设备临床数据；数据受严格的 GDPR 和 MDR（医疗器械法规）合规性约束；访问可能需要匿名化协议 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Eumediq 拥有一个专有的医疗影像数据集，该数据集已根据欧洲医疗器械法规系统地收集和分析用于临床评估报告。这些结构化数据，连同上市后监管和风险管理文件，是医疗人工智能公司开发诊断影像算法的稀有资产。在全球医疗影像人工智能市场预计从目前 17.5 亿美元的估值每年增长 30% 的情况下，该数据集为模型验证和监管批准提供了关键优势。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
人工智能买家需求异常高，这得益于医疗影像人工智能市场以 30% 的复合年增长率快速扩张，从而产生了对高质量、合规临床数据的迫切需求。[7]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=已拥有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，5 个近期外部信号 — 超出已货币化数据的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ 审查 — Eumediq 是一家监管咨询公司和 SaaS 提供商，其核心业务是向 MedTech 行业销售服务和情报，因此它不是一个好的目标，因为它不持有专有的运营数据。问题：公司核心业务是销售服务和情报（咨询、人工智能软件），这属于明确的排除标准。[2, 5, 12]；不拥有非数据业务副产品生成的专有数据；它是一家纯粹的服务/SaaS 供应商。[5, 6]；
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<p>Whoop made changes to its blood pressure insights feature that satisfied the FDA’s requirements for wellness devices.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/kNDxaHd14-f10nWBdgWe6x6pY6uAtvNrmd0oeK6qGmI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjQwODk4NDg4LmpwZw==.webp" /></div></figure><p>The new organization supporting healthcare and pharmaceutical services fuels efforts to grow high-value customer segments as less-lucrative volume declines.</p>”
- “<p>Overseas markets are central to MiniMed’s business, accounting for 70% of reported net sales in the company’s 2026 financial year.</p>”
Medical records / imaging
这些证据表明数据集包含已进行正式临床数据分析的医疗影像，用于欧洲监管提交，为人工智能模型训练和验证提供了重要背景。
Regulatory records
这证明了上市后监管的既定流程，提供了持续的真实世界绩效数据流，这对于持续的人工智能模型监控和满足监管义务至关重要。
Industrial data
这表明存在结构化的技术文档和风险管理文件，这些文件确立了清晰的数据出处，对于降低商业诊断人工智能工具的开发风险至关重要。
Marketplace
Dataset details
Geographic coverage
Global
Time range
Periodic (specific range not provided, assumed ongoing)
Update frequency
Periodic
Delivery
Likely secure file transfer or dedicated access
Formats
DICOM
License
Subject to strict GDPR and MDR compliance; usage likely restricted to AI model training, testing, and validation.
Personal data
Contains PII
Indicative estimate, derived from public signals — not a quote, not contractual, and not agreed with the company. Is this your company? Correct it.
This proprietary medical imaging dataset, enriched with clinical and regulatory data, is highly valuable for diagnostic AI development in a high-growth market. Its rarity and the stringent compliance requirements (GDPR, MDR) justify a premium valuation.
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Eumediq Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.75B in 2024, CAGR 30% (source: rootsanalysis.com) [7]. Investment score 45.0/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Quintasenergy — 维护日志数据集机会
View opportunity →其他Wondrwall — 传感器遥测数据集机会
View opportunity →出行Fleetalliance — 维护日志数据集机会
View opportunity →